datopotamab deruxtecan
AstraZeneca shares results from phase 3 TROPION-Lung01 trial
May 28, 2024Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
March 4, 2024Medical Communications CHMP, Daiichi Sankyo, EMA, Oncology, datopotamab deruxtecan
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications (MAAs) for AstraZeneca and Daiichi …
AstraZeneca shares results from phase 3 trial of datopotamab deruxtecan for NSCLC
July 3, 2023Medical Communications AstraZeneca, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
AstraZeneca has announced results from its TROPION-Lung01 phase 3 trial for its TROP2-directed antibody drug conjugate, developed in collaboration with …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
